New Strategies for Treating GIST When Imatinib Fails

REFERENCES

• DeMatteo R. P., Lewis J. J., Leung D., Mudan S. S., Woodruff J. M., Brennan M. F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000; 231(1)51–58
   PubMed Web of Science ®Google Scholar
• Dematteo R. P., Heinrich M. C., El-Rifai W. M., Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 2002; 33(5)466–477
   PubMed Web of Science ®Google Scholar
• Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Tunio G. M., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279(5350)577–580
   PubMed Web of Science ®Google Scholar
• Manley P. W., Cowan-Jacob S. W., Buchdunger E., Fabbro D., Fendrich G., Furet P., Meyer T., Zimermann J. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 2002; 38: S19–S27, (Suppl. 5)
   PubMed Web of Science ®Google Scholar
• Demetri G. D., von Mehren M., Blanke C. D., Van den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B. J., Corless C., Fletcher C. D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347(7)472–480
   PubMed Web of Science ®Google Scholar
• Verweij J., Casali P. G., Zalcberg J., LeCesne A., Reichardt P., Blay J. Y., Issels R., van Oosterom A., Hogendoorn P. C., Van Glabbeke M., Bertulli R., Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440)1127–1134
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M., Verweij J., Casali P. G., Le Cesne A., Hohenberger P., Ray-Coquard I., Schlemmer M., van Oosterom A. T., Goldstein D., Sciot R., Hogendoorn P. C.W., Brown M., Bertulli R., Judson I. R. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-italian sarcoma group-australasian gastrointestinal trials group study. J. Clin. Oncol. 2005; 23(24)5795–5804
   PubMed Web of Science ®Google Scholar
• Fletcher C. D., Berman J. J., Corless C., Gorstein F., Lasota J., Longley B. J., Miettinen M., O'Leary T. J., Remotti H., Rubin B. P., Shmookler B., Sobin L. H., Weiss S. W. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002; 33(5)459–465
   PubMed Web of Science ®Google Scholar
• Miettinen M., Majidi M., Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur. J. Cancer 2002; 38: S39–S51, (Suppl. 5)
   PubMed Web of Science ®Google Scholar
• Connolly E. M., Gaffney E., Reynolds J. V. Gastrointestinal stromal tumours. Br. J. Surg. 2003; 90(10)1178–1186
   PubMed Web of Science ®Google Scholar
• Graadt v an, Roggen J. F., van Velthuysen M. L.F., Hogendoorn P. C.W. The histopathological differential diagnosis of gastrointestinal stromal tumours. J. Clin. Pathol. 2001; 54(2)96–102
   PubMed Web of Science ®Google Scholar
• Wang L., Vargas H., French S. W. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases. Arch. Pathol. Lab. Med. 2000; 124(10)1471–1475
   PubMed Web of Science ®Google Scholar
• Lux M. L., Rubin B. P., Biase T. L., Chen C. J., Maclure T., Demetri G., Xiao S., Singer S., Fletcher C. D.M., Fletcher J. A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 2000; 156(3)791–795
   PubMed Web of Science ®Google Scholar
• Broudy V. C. Stem cell factor and hematopoiesis. Blood 1997; 90(4)1345–1364
   PubMed Web of Science ®Google Scholar
• Lasota J., Jasinski M., Sarlomo-Rikala M., Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 1999; 154(1)53–60
   PubMed Web of Science ®Google Scholar
• Chen L. L., Sabripour M., Andtbacka R. H.I., Patel S. R., Feig B. W., Macapinlac H. A., Choi H., Wu E. F., Frazier M. L., Benjamin R. S. Imatinib resistance in gastrointestinal stromal tumors. Curr. Oncol. Rep. 2005; 7(4)293–299
   PubMedGoogle Scholar
• Heinrich M. C., Corless C. L., Demetri G. D., Blanke C. D., von Mehren M., Joensuu H., McGreevey L. S., Chen C. J., Van den Abbeele A. D., Druker B. J., Kiese B., Eisenberg B., Roberts P. J., Singer S., Fletcher C. D.M., Silberman S., Dimitrijevic S., Fletcher J. A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21(23)4342–4349
   PubMed Web of Science ®Google Scholar
• Miettinen M., El-Rifai W., Sobin L. H., Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum. Pathol. 2002; 33(5)478–483
   PubMed Web of Science ®Google Scholar
• Heinrich M. C., Corless C. L., Duensing A., McGreevey L., Chen C. J., Joseph N., Singer S., Griffith D. J., Haley A., Town A., Demetri G. D., Fletcher C. D.M., Fletcher J. A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299(5607)708–710
   PubMed Web of Science ®Google Scholar
• Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S., Zimmermann J., Lydon N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996; 2(5)561–566
   PubMed Web of Science ®Google Scholar
• Heinrich M. C., Griffith D. J., Druker B. J., Wait C. L., Ott K. A., Zigler A. J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96(3)925–932
   PubMed Web of Science ®Google Scholar
• Druker B. J., Sawyers C. L., Kantarjian H., Resta D. J., Reese S. F., Ford J. M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001; 344(14)1038–1042
   PubMed Web of Science ®Google Scholar
• Mol C. D., Dougan D. R., Schneider T. R., Skene R. J., Kraus M. L., Scheibe D. N., Snell G. P., Zou H., Sang B. C., Wilson K. P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 2004; 279(30)31655–31663
   PubMed Web of Science ®Google Scholar
• van Oosterom A. T., Judson I. R., Verweij J., Stroobants S., Dumez H., Donato di Paola E., Sciot R., Van Glabbeke M., Dimitrijevic S. L., Nielsen O. S. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2002; 38: S83–S87, (Suppl. 5)
   PubMed Web of Science ®Google Scholar
• Corless C. L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., Shiraga S., Bainbridge T., Morich J., Heinrich M. C. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 2005; 23(23)5357–5364
   PubMed Web of Science ®Google Scholar
• Linton K. M., Taylor M. B., Radford J. A. Response evaluation in GIST treated with imatinib—misdiagnosis of disease progression on CT due to cystic change in liver metastases. Proc. Amer. Soc. Clin. Oncol. 2005, (Abstr. 9047)
   Web of Science ®Google Scholar
• Choi H., Charnsangavej C., de Castro Faria S., Tamm E. P., Benjamin R. S., Johnson M. M., Macapinlac H. A., Podoloff D. A. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am. J. Roentgenol. 2004; 183(6)1619–1628
   PubMed Web of Science ®Google Scholar
• Stroobants S., Goeminne J., Seegers M., Dimitrijevic S., Dupont P., Nuyts J., Martens M., van den Borne B., Cole P., Sciot R., Dumez H., Silberman S., Mortelmans L., van Oosterom A. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 2003; 39(14)2012–2020
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Bonvalot S., Casali P., Choi H., Debiec-Richter M., Dei Tos A. P., Emile J. F., Gronchi A., Hogendoorn P. C.W., Joensuu H., Le Cesne A., Mac Clure J., Maurel J., Nupponen N., Ray-Coquard I., Reichardt P., Sciot R., Stroobants S., van Glabbeke M., van Oosterom A., Demetri G. D. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann. Oncol. 2005; 16(4)566–578
   PubMed Web of Science ®Google Scholar
• Rankin C., Von Mehren M., Blanke C., Benjamin R., Fletcher C. D.M., Bramwell V., Crowley J., Borden E., Demetri G. D. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. Proc. Amer. Soc. Clin. Oncol. J. Clin. Oncol. 2004; 22: 9005, (Suppl. 14)
   Google Scholar
• Chen L. L., Trent J. C., Wu E. F., Fuller G. N., Ramdas L., Zhang W., Raymond A. K., Prieto V. G., Oyedeji C. O., Hunt K. K., Pollock R. E., Feig B. W., Hayes K. J., Choid H., Macapinlac H. A., Hittelman W., Velasco M. A., Patel S., Burgess M. A., Benjamin R. S., Frazier M. L. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer. Res. 2004; 64(17)5913–5919
   PubMed Web of Science ®Google Scholar
• Shankar S., vanSonnenberg E., Desai J., Dipiro P. J., Van Den Abbeele A., Demetri G. D. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235(3)892–898
   PubMed Web of Science ®Google Scholar
• Gorre M. E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P. N., Sawyers C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531)876–880
   PubMed Web of Science ®Google Scholar
• Fletcher J. A., Corless C. L., Dimitrijevic S., Von Mehren M., Eisenberg B., Joensuu H., Fletcher C. D.M., Blanke C., Demetri G. D., Heinrich M. C. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc. Amer. Soc. Clin. Oncol. 2003, (Abstr. 3275)
   PubMedGoogle Scholar
• Antonescu C. R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., Leversha M. A., Jeffrey P. D., Desantis D., Singer S., Brennan M. F., Maki R. G., DeMatteo R. P. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer. Res. 2005; 11(11)4182–4190
   PubMed Web of Science ®Google Scholar
• Zalcberg J. R., Verweij J., Casali P. G., Le Cesne A., Reichardt P., Blay J. Y., Issels R. D., Van Glabbeke M., Evrard V., Judson I. R. Outcome of patients with advanced gastrointestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD)—an international, intergroup study of the EORTC, ISG and AGITG. Proc. Amer. Soc. Clin. Oncol. J. Clin. Oncol. 2004; 22, (Suppl. 14), (Abstr. 9004)
   Google Scholar
• Dileo P., Randhawa R., Vansonnenberg E., Shankar S., Desai J., Morgan J. A., Tuncali K., Van Den Abbeele A., Silverman S. G., Demetri G. D. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate. Proc. Amer. Soc. Clin. Oncol. J. Clin. Oncol. 2004; 22, (Suppl. 14), (Abstr. 9024)
   Google Scholar
• Bauer S., Hartmann J. T., Lang H., Antoch G., Dirsch O., Ebeling P., De Wit M., Seeber S., Flasshove M., Schutte J. Imatinib may enable complete resection in previously unresectable or metastatic GIST. Proc. Amer. Soc. Clin. Oncol. J. Clin. Oncol. 2004; 22, (Suppl. 14), (Abstr. 9023)
   Google Scholar
• Rutkowski P., Nowecki Z., Nyckowski P., Dzierwirski W., Nasierowska-Guttmejer A., Grzesiakowska U., Michej W., Krawczyk M., Ruka W. Surgical treatment of patients with gastrointestinal stromal tumors (GIST) after imatinib mesylate therapy. Proc. Amer. Soc. Clin. Oncol. 2005, (Abstr. 9037)
   Google Scholar
• Raut C. P., Posner M., Desai J., Morgan J. A., George S., Zahrieh D., Fletcher C. D.M., Demetri G. D., Bertagnolli M. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. 2006; 24: 2325–2331
   PubMed Web of Science ®Google Scholar
• FDA Approves New Treatment for Gastrointestinal and Kidney Cancer, P06-11. U.S. Food and Drug Administration, Rockville, MD 2006, http://www.fda.gov/bbs/topics/news/2006/NEW01302.html
   Google Scholar
• Demetri G. D., Desai J., Fletcher J. A., Morgan J. A., Fletcher C. D.M., Kazanovicz A., Van Den Abbeele A., Baum C., Maki R., Heinrich M. C. SU11248, a multi-targeted tyrosine kinase inhibitor, an overcome imatinib resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor. Proc. Amer. Soc. Clin. Oncol. J. Clin. Oncol. 2004; 22, (Suppl. 14), (Abstr. 3001)
   Google Scholar
• Demetri G. D., van Oosterom A. T., Blackstein M., Garrett C., Shah M., Heinrich M., McArthur G., Judson I., Baum C. M., Casali P. G. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. Proc. Amer. Soc. Clin. Oncol. 2005, (Abstr. 4000)
   Google Scholar
• Demetri G., van Oosterom A. T., Garrett C., Blackstein M., Shah M., Verweij J. J., McArthur G., Judson I., Casali C. I. Improved survival and sustained clinical benefit with SU11248 in pts with GIST after failure of imatinib mesylate therapy in a phase III trial. Proc. Amer. Soc. Clin. Oncol. 2006, (Abstr. 8)
   Google Scholar
• SUTENT [Package insert]. Pfizer, Inc., New York, NY 2006
   Google Scholar
• Desai J., Dileo P., Morgan J. A., Larsen P. R., Chen M. H., George S., Jackson J., Baum C., Demetri G. D. Hypothyroidism may accompany SU11248 therapy in a subset of patients with metastatic gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy. Proc. Amer. Soc. Clin. Oncol. J. Clin. Oncol. 2005; 23, (Suppl. 16), (Abstr. 3040)
   Google Scholar
• Davis D. W., McConkey D. J., Heymach J. V., Desai J., George S., Jackson J., Bello C. L., Baum C., Shalinsky D. R., Demetri G. D. Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248. Proc. Amer. Soc. Clin. Oncol. 2005, (Abstr. 3006)
   Web of Science ®Google Scholar
• Evans T. R., Morgan J. A., van den Abbeele A. D., McPherson I. R., George S., Crawford D., Mastrullo J. M., Cheng S., Fletcher J. A., Demetri G. D. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients with GIST and other solid tumors. Proc. Amer. Soc. Clin. Oncol. 2005, (Abstr. 3034)
   Google Scholar
• van Oosterom A., Reichardt P., Blay J., Dumez H., Fletcher J., Debiec-Rychter M., Shand N., Dimitrijevic S., Yap A., Demetri G. A phase I/II trial of the oral mTOR-inhibitor Everolimus and Imtinib mesylate in patients with gastrointestinal stromal tumor refractory to IM: Study update. Proc. Amer. Soc. Clin. Oncol. 2005, (Abstr. 9033)
   Web of Science ®Google Scholar
• Propper D. J., McDonald A. C., Man A., Thavasu P., Balkwill F., Braybrooke J. P., Caponigro F., Graf P., Dutreix C., Blackie R., Kaye S. B., Ganesan T. S., Talbot D. C., Harris A. L., Twelves C. Phase I and pharmacodynamic study of PKC412, an inhibitor of protein kinase. C. J. Clin. Oncol. 2001; 19(5)1485–1492
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M., Cools J., Dumez H., Sciot R., Stul M., Mentens N., Vranckx H., Wasag B., Prenen H., Roesel J., Hagemeijer A., Van Oosterom A., Marynen P. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270–279
   PubMed Web of Science ®Google Scholar
• Reichardt P., Pink D., Lindner T., Heinrich M. C., Cohen P. S., Wang Y., Yu R., Tsyrlova A., Dimitrijevic S., Blanke C. A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate in patients with gastrointestinal stromal tumor refractory to IM. Proc. Amer. Soc. Clin. Oncol. 2005, (Abstr. 3016)
   Google Scholar
• Feakins R. M. The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 2005; 46(3)270–279
   PubMed Web of Science ®Google Scholar
• Blair S. L., Al-Refaie W. B., Wang-Rodriguez J., Behling C., Ali M. W., Moossa A. R. Gastrointestinal stromal tumors express ras oncogene. Arch. Surg. 2005; 140: 543–548
   PubMed Web of Science ®Google Scholar